EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial

Stefan R Bornstein, Dick de Zeeuw iD, Hiddo J L Heerspink iD, Friedrich Schulze iD, Lisa Cronin, Arne Wenz, Katherine R Tuttle iD, Samy Hadjadj iD, Peter Rossing iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15518 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Stefan R Bornstein und 8 weiteren Autor:innen. Beteiligte Einrichtung: Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Albuminuria. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This Phase I study evaluated the safety and early efficacy of an aldosterone synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney disease.

Methods

Double‐blind, placebo‐controlled study (NCT03165240) at 40 sites across Europe. Eligible participants [estimated glomerular filtration rate ≥20 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicAlbuminuriaHumansDouble-Blind MethodMaleFemaleMiddle AgedAgedMineralocorticoid Receptor AntagonistsAdultTreatment OutcomeCytochrome P-450 CYP11B2EplerenoneDiabetic NephropathiesGlomerular Filtration RateDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

Phase I‐II studydrug developmentpharmacodynamicspharmacokineticstype 1 diabetestype 2 diabetes

Substanzen

Mineralocorticoid Receptor AntagonistsCytochrome P-450 CYP11B2Eplerenone

Autor:innen und Institutionen

  • Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany.
  • Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
  • Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Providence Health Care, University of Washington, Spokane, Washington, USA.

ORCID-Profile: Dick de Zeeuw, Hiddo J L Heerspink, Friedrich Schulze, Katherine R Tuttle, Samy Hadjadj, Peter Rossing

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Bornstein, S. R., de Zeeuw, D., Heerspink, H. J. L., Schulze, F., Cronin, L., Wenz, A., Tuttle, K. R., Hadjadj, S., & Rossing, P. (2024). Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15518

Vancouver

Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, et al. Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15518

BibTeX
@article{Bornstein2024,
  author = {Bornstein, Stefan R and de Zeeuw, Dick and Heerspink, Hiddo J L and Schulze, Friedrich and Cronin, Lisa and Wenz, Arne and Tuttle, Katherine R and Hadjadj, Samy and Rossing, Peter},
  title = {Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15518}
}
Kostenlos starten →